The Bloom #190 Free Edition pen-ultimate email, from here

Hi there,

This will be the last 'The Bloom' sent from the old email system.

You will get a new email next Monday at 4 pm European time (morning for the US).

And that is because the new website is now officially live 🎉

It's been quite a journey - which mostly happened behind the scenes - to fully rebuild the database. But looking back, I'm very happy with how things have turned out.

On the new site there is a lot more information available for each paper, better overview pages, cool new visualisations like the Atlas and Research Groups pages.

I've also made a quick video about psychedelic research (90 seconds long), which you can find here.

Thank you for being with me on this amazing journey through psychedelic research. I will see you on the other side.

With gratitude,
Floris

P.S. Your email address should already be registered on the new site and you should have gotten a few introductory emails. If not, go to moreblossom.com, enter this email address, and you'll get a login code.

P.P.S. See anything broken, missing, wonky? Leave some feedback on the Roadmap, or hit reply.

Latest Psychedelic Research

1 Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial​

In this triple‑blind, active placebo‑controlled randomised trial (n=144) of adults with treatment‑resistant depression, two 25 mg doses of psilocybin plus adjunct psychotherapy produced clinically meaningful reductions in depressive symptoms on exploratory secondary measures but did not significantly improve the pre‑second‑dose HAMD17 response rate versus nicotinamide.

2 Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions A Systematic Review and Meta-Analysis​

This meta-analysis (s=24) found that psychedelic-assisted therapy (s=8) was no more effective than open-label traditional antidepressants for treating major depression, and that, unlike traditional antidepressants (where blinding meaningfully influenced outcomes), PAT trials showed no difference between blinded and open-label conditions, confirming that PAT trials are effectively always unblinded.

3 GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial​

This randomised, double-blind, placebo-controlled Phase IIb trial (n=81) found that a single-day inhaled synthetic mebufotenin treatment (GH001; 5-MeO-DMT) reduced depression symptoms more than placebo in adults with treatment-resistant depression, with remission in over half of those treated. No severe or serious adverse events were reported during the placebo-controlled period.

4 Trip killers: Addressing a critical knowledge gap in psychedelic research​

This review examines medicines that might be used to stop or reduce severe distress during a psychedelic “bad trip”, focusing on serotonin antagonists, antipsychotics, and some anxiety and depression drugs. It also considers how these drugs work, how quickly they act, their safety, and how they might be used in emergency care.

5 Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin​

This commentary discusses how psilocybin could be delivered in publicly funded health services such as the NHS, focusing on the role of psychological support alongside the drug. It outlines a possible service model and emphasises that implementation should be grounded in strong evidence and equitable access.

6 Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants​

This double-blind, randomised, placebo-controlled crossover study and separate open-label dose-escalation study (n=36) in healthy participants examined intravenous DMT and found that it produced very strong but short-lived subjective effects, peaking within 2 minutes and fading within 12 to 30 minutes. The strongest effects levelled off at 15 mg, and dose escalation appeared to improve tolerability compared with blinded dosing.

New on Blossom

​

1 Atlas of Psychedelic Research​

Where do the psychedelic research trials take place? And did you know there are now over 1000 of them? Find all on the Atlas. Filter by year, topic, compound, etc.

2 Events Page​

Discover upcoming psychedelic conferences, scientific summits, and local gatherings. Filter by location, date, and format to find your next gathering.

(like ICPR where I will be again this year)

Molenvaart 76, Anna Paulowna, NH 1761AL
​Unsubscribe · Preferences​